Literature DB >> 29472279

Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation.

Monika Morak1,2, Ayseguel Ibisler3, Gisela Keller4, Ellen Jessen5, Andreas Laner2, Daniela Gonzales-Fassrainer2, Melanie Locher2, Trisari Massdorf1, Anke M Nissen2, Anna Benet-Pagès2, Elke Holinski-Feder1,2.   

Abstract

BACKGROUND: Germline defects in MLH1, MSH2, MSH6 and PMS2 predisposing for Lynch syndrome (LS) are mainly based on sequence changes, whereas a constitutional epimutation of MLH1(CEM) is exceptionally rare. This abnormal MLH1 promoter methylation is not hereditary when arising de novo, whereas a stably heritable and variant-induced CEM was described for one single allele. We searched for MLH1 promoter variants causing a germline or somatic methylation induction or transcriptional repression.
METHODS: We analysed the MLH1 promoter sequence in five different patient groups with colorectal cancer (CRC) (n=480) composed of patients with i) CEM (n=16), ii) unsolved loss of MLH1 expression in CRC (n=37), iii) CpG-island methylator-phenotype CRC (n=102), iv) patients with LS (n=83) and v) MLH1-proficient CRC (n=242) as controls. 1150 patients with non-LS tumours also served as controls to correctly judge the results.
RESULTS: We detected 10 rare MLH1 promoter variants. One novel, complex MLH1 variant c.-63_-58delins18 is present in a patient with CRC with CEM and his sister, both showing a complete allele-specific promoter methylation and transcriptional silencing. The other nine promoter variants detected in 17 individuals were not associated with methylation. For four of these, a normal, biallelic MLH1 expression was found in the patients' cDNA.
CONCLUSION: We report the second promoter variant stably inducing a hereditary CEM. Concerning the classification of promoter variants, we discuss contradictory results from the literature for two variants, describe classification discrepancies between existing rules for five variants, suggest the (re-)classification of five promoter variants to (likely) benign and regard four variants as functionally unclear. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  cancer: colon; epigenetics; genetic screening/counselling; genetics

Mesh:

Substances:

Year:  2018        PMID: 29472279     DOI: 10.1136/jmedgenet-2017-104744

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  10 in total

1.  Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.

Authors:  Monika Morak; Verena Steinke-Lange; Trisari Massdorf; Anna Benet-Pages; Melanie Locher; Andreas Laner; Katrin Kayser; Stefan Aretz; Elke Holinski-Feder
Journal:  Fam Cancer       Date:  2020-04       Impact factor: 2.375

2.  Targeted deep-intronic sequencing in a cohort of unexplained cases of suspected Lynch syndrome.

Authors:  Dimitrij Frishman; Elke Holinski-Feder; Anke Marie Arnold; Monika Morak; Anna Benet-Pagès; Andreas Laner
Journal:  Eur J Hum Genet       Date:  2019-12-10       Impact factor: 4.246

Review 3.  Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.

Authors:  William M Grady; Ming Yu; Sanford D Markowitz
Journal:  Gastroenterology       Date:  2020-12-03       Impact factor: 22.682

Review 4.  Advances in Identification of Susceptibility Gene Defects of Hereditary Colorectal Cancer.

Authors:  Qiang Liu; Yue-Qiu Tan
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

5.  Effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells.

Authors:  Lingqin Zhao; Huafeng Shou; Lu Chen; Wen Gao; Chenyan Fang; Ping Zhang
Journal:  Oncol Rep       Date:  2019-04-12       Impact factor: 3.906

6.  Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation.

Authors:  Estela Dámaso; Júlia Canet-Hermida; Gardenia Vargas-Parra; Àngela Velasco; Fátima Marín; Esther Darder; Jesús Del Valle; Anna Fernández; Àngel Izquierdo; Gemma Mateu; Glòria Oliveras; Carmen Escribano; Virgínia Piñol; Hugo-Ikuo Uchima; José Luis Soto; Megan Hitchins; Ramon Farrés; Conxi Lázaro; Bernat Queralt; Joan Brunet; Gabriel Capellá; Marta Pineda
Journal:  Clin Epigenetics       Date:  2019-11-28       Impact factor: 6.551

7.  Rare germline variants in DNA repair-related genes are accountable for papillary thyroid cancer susceptibility.

Authors:  Marialuisa Sponziello; Giuseppe Damante; Catia Mio; Antonella Verrienti; Valeria Pecce
Journal:  Endocrine       Date:  2021-04-05       Impact factor: 3.633

Review 8.  DNA Methylation in the Diagnosis of Monogenic Diseases.

Authors:  Flavia Cerrato; Angela Sparago; Francesca Ariani; Fulvia Brugnoletti; Luciano Calzari; Fabio Coppedè; Alessandro De Luca; Cristina Gervasini; Emiliano Giardina; Fiorella Gurrieri; Cristiana Lo Nigro; Giuseppe Merla; Monica Miozzo; Silvia Russo; Eugenio Sangiorgi; Silvia M Sirchia; Gabriella Maria Squeo; Silvia Tabano; Elisabetta Tabolacci; Isabella Torrente; Maurizio Genuardi; Giovanni Neri; Andrea Riccio
Journal:  Genes (Basel)       Date:  2020-03-26       Impact factor: 4.096

9.  BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?

Authors:  Per Eystein Lønning; Stian Knappskog
Journal:  Clin Epigenetics       Date:  2018-10-22       Impact factor: 6.551

10.  A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.

Authors:  D Gareth R Evans; Elke M van Veen; Helen J Byers; Andrew J Wallace; Jamie M Ellingford; Glenda Beaman; Javier Santoyo-Lopez; Timothy J Aitman; Diana M Eccles; Fiona I Lalloo; Miriam J Smith; William G Newman
Journal:  Am J Hum Genet       Date:  2018-08-02       Impact factor: 11.025

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.